ドキソルビシンの市場規模、シェア、成長分析：処方別、流通別、用途別、地域別 - 産業予測 2025～2032年

ドキソルビシンの世界市場規模は2023年に9億7,650万米ドルと評価され、2024年の10億3,997万米ドルから2032年には17億2,115万米ドルに成長し、予測期間（2025～2032年）のCAGRは6.5%で推移する見通しです。

ドキソルビシンの世界市場は、アントラサイクリン系の代表的な化学療法剤であり、乳がん、肺がん、白血病など様々ながんに対する有効性から堅調な需要があります。2022年には世界中で2,000万人近くが新たにがんと診断され、高齢化に伴うヘルスケアニーズの高まりから、ドキソルビシンのような効果的な治療薬の重要性が高まっています。ドラッグデリバリーシステムの改善や医薬品開発の進歩により、安全性と有効性が向上し、がん治療における受容性が高まっています。全米総合がん対策プログラムなどの政府の取り組みは、資金援助や啓発キャンペーンを通じて市場の成長をさらに後押ししています。しかし、潜在的な副作用が市場拡大の妨げになる可能性がある一方で、個別化医療や新規併用療法における研究開発の進行が新たな市場機会をもたらしています。全体として、ドキソルビシン市場は大きな成長を遂げようとしています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 規制情勢
• ケーススタディ
• 技術分析

ドキソルビシン市場規模：処方別

• 市場概要
• 凍結乾燥粉末
• ドキソルビシン注射剤

ドキソルビシン市場規模：流通別

• 市場概要
• 病院薬局
• 小売薬局
• オンライン薬局

ドキソルビシン市場規模：用途別

• 市場概要
• 膀胱がん
• カポジ肉腫
• 白血病
• リンパ腫
• 乳がん
• その他

ドキソルビシン市場規模

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022～2024年）

主要企業プロファイル

• Pfizer Inc.（USA）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Mylan N.V.（USA）
• Novartis AG（Switzerland）
• Bristol-Myers Squibb（USA）
• Roche Holding AG（Switzerland）
• Eli Lilly and Company（USA）
• Boehringer Ingelheim GmbH（Germany）
• Sandoz International GmbH（Switzerland）
• Amgen Inc.（USA）
• Dr. Reddy's Laboratories（India）
• Lupin Pharmaceuticals, Inc.（India）
• Sun Pharmaceutical Industries Ltd.（India）
• Aurobindo Pharma（India）
• Cipla Ltd.（India）
• Zydus Cadila（India）
• Hikma Pharmaceuticals（Jordan）
• Apotex Inc.（Canada）
• Mochida Pharmaceutical Co., Ltd.（Japan）

結論と提言

Global Doxorubicin Market size was valued at USD 976.5 million in 2023 and is poised to grow from USD 1039.97 million in 2024 to USD 1721.15 million by 2032, growing at a CAGR of 6.5% during the forecast period (2025-2032).

The global doxorubicin market, a leading chemotherapeutic agent in the anthracycline class, is experiencing robust demand due to its efficacy against various cancers, including breast, lung, and leukemia. With nearly 20 million new cancer diagnoses worldwide in 2022, the aging population's increasing healthcare needs underscore the rising importance of effective treatments like doxorubicin. Improved drug delivery systems and advancements in drug development are enhancing its safety and effectiveness, promoting greater acceptance in cancer therapies. Government initiatives, such as the National Comprehensive Cancer Control Program, are further supporting market growth through funding and awareness campaigns. However, potential side effects may hinder expansion, while ongoing R&D efforts in personalized medicine and novel combination therapies present new market opportunities. Overall, the doxorubicin market is poised for significant growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Doxorubicin market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Doxorubicin Market Segments Analysis

Global Doxorubicin Market is segmented by Formulation, Distribution, Application and region. Based on Formulation, the market is segmented into Lyophilized Powder and Doxorubicin Injection. Based on Distribution, the market is segmented into Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies. Based on Application, the market is segmented into Bladder Cancer, Kaposi Sarcoma, Leukemia, Lymphoma, Breast Cancer and Other. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Doxorubicin Market

The global doxorubicin market is significantly driven by the rising prevalence of cancer worldwide. As a highly effective anticancer agent, doxorubicin is utilized extensively for the treatment of various cancers, such as breast cancer, ovarian cancer, leukemia, and lymphoma. Recent cancer statistics highlight a growing cancer burden, particularly in developing nations, which has led to an escalated demand for effective cancer therapies. This surge in cancer cases emphasizes the crucial role of doxorubicin in oncology, propelling its market growth and underscoring the need for innovative treatment options to combat this global health crisis.

Restraints in the Global Doxorubicin Market

The global doxorubicin market faces significant constraints primarily due to the drug's associated toxicities. Doxorubicin is recognized for its cardiotoxic effects, which can lead to chronic cardiac complications in patients undergoing treatment. Such serious concerns have prompted both healthcare professionals and patients to seek alternative therapies that offer fewer side effects. Additionally, doxorubicin can cause adverse reactions such as nausea, inflammation, and myelosuppression, which further restrict its tolerability among specific patient populations. These factors collectively hinder the growth of the doxorubicin market, as the pursuit of safer oncological options continues to gain momentum.

Market Trends of the Global Doxorubicin Market

The global Doxorubicin market is experiencing a notable trend toward the rising adoption of liposomal formulations, exemplified by products like Doxil. These innovative therapies are increasingly favored for their capability to minimize toxicity while ensuring targeted drug delivery to tumor sites, addressing a critical need in oncology. The surge in demand is bolstered by robust research and development initiatives and a wave of regulatory approvals anticipated in the near future. This trend particularly benefits elderly and high-risk patients who may not tolerate traditional doxorubicin, suggesting a shift toward more patient-centric treatment approaches and a promising growth trajectory for the market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Analysis

Global Doxorubicin Market Size by Formulation & CAGR (2025-2032)

• Market Overview
• Lyophilized Powder
• Doxorubicin Injection

Global Doxorubicin Market Size by Distribution & CAGR (2025-2032)

• Market Overview
• Hospitals Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Doxorubicin Market Size by Application & CAGR (2025-2032)

• Market Overview
• Bladder Cancer
• Kaposi Sarcoma
• Leukemia
• Lymphoma
• Breast Cancer
• Other

Global Doxorubicin Market Size & CAGR (2025-2032)

• North America (Formulation, Distribution, Application)
  • US
  • Canada
• Europe (Formulation, Distribution, Application)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Formulation, Distribution, Application)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Formulation, Distribution, Application)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Formulation, Distribution, Application)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz International GmbH (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Pharmaceuticals, Inc. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Cadila (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals (Jordan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Apotex Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mochida Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations